Gilead Sciences said Friday additional data from a late-stage study showed its antiviral remdesivir reduced the risk of death and significantly improved the conditions of severely ill COVID-19 patients.
The antiviral drug Remdesivir has proven to be effective in the treatment of COVID-19. According to UPI, the drug can lower the risk of death in COVID-19 patients by 62%. U.S. drugmaker Gilead Sciences reported the new data on Friday. Gilead said the results came from a comparative analysis among 312 patients in its Phase 3 clinical trial. There have been over 3.4 million confirmed cases of coronavirus in the U.S., with a death toll of 138,247 people.
U.S. stocks rose Friday as a positive analysis on Gilead Sciences Inc's antiviral drug to treat COVID-19 helped to soothe investor worries over a record rise in coronavirus cases in the United States. Fred Katayama reports.
The European Commission said Friday it had given conditional approval for the use of antiviral drug remdesivir in severe COVID-19 patients. As Fred Katayama reports, that makes it the region's first authorized therapy to treat the virus.
John Hancock Global Thematic Opportunities Fund's Gert Van Der Geer identifies long-term themes that haven't played out in the market yet. He tells Reuters' Fred Katayama medical technology companies such as Boston Scientific and Edwards will bounce back once people undergo elective surgeries that they put off amid the lockdown.
Teladoc Health has agreed to buy chronic care provider Livongo Health in a deal valuing the company at $18.5 billion that bets on a boom in online care and consultations spurred by the coronavirus crisis. Fred Katayama reports.
Wall Street ended higher after a choppy session on Tuesday, but they were capped by declines in AIG and Microsoft. As Fred Katayama reports, Disney shares shot higher after its adjusted profit handily beat expectations.
Ralph Lauren said Tuesday its quarterly revenue plunged by nearly $1 billion, as it struggled with coronavirus-led store closures and a global slowdown in demand for luxury goods. Fred Katayama reports.
The Nasdaq jumped more than 1% on Friday, powered by strong earnings from some of the largest U.S. companies, but the Dow and S&P finished with smaller gains as uncertainty about the government's next round of coronavirus aid kept economic worries on the radar. Fred Katayama reports.